Targeted Cancer Therapy: Biomarkers, Mechanisms, Resistance and Drug Safety

Evidence and references reviewed 10 November 2026.

A molecular test can change which medicine an oncology team considers for two patients with the same tumour type. Targeted drugs act on proteins involved in cancer growth or survival. For many treatments, the decision requires the exact molecular finding, the stage of disease and the patient’s prior treatment.1,2,3

What makes targeted cancer treatment different?

Targeted therapies interfere with a molecule or pathway that promotes cancer-cell growth, survival, angiogenesis or DNA repair. Unlike the broad tissue injury caused by many conventional cytotoxic drugs, target-directed treatment can exploit a particular oncogenic driver or molecular vulnerability. However, the word targeted does not mean harmless or that a medicine affects cancer cells exclusively. Targeted agents may cause severe skin, heart, lung, liver, eye and blood-cell toxicity, depending on their mechanism.1

A predictive biomarker helps identify a patient likely to benefit from a particular therapy; a prognostic biomarker informs expected disease course independently of that treatment. The two may overlap but are not interchangeable. Results can come from tissue biopsy, immunohistochemistry, in situ hybridization, next-generation sequencing or a validated liquid biopsy. Testing must account for tumor type, stage, sampling adequacy, assay limitations and which companion diagnostic is indicated.

Reading a biomarker result

In non-small cell lung cancer, the report may identify an EGFR exon 19 deletion, an EGFR exon 21 L858R mutation, or an ALK or ROS1 rearrangement. These findings lead to different treatment options. Osimertinib has indications for defined EGFR-mutated disease, including adjuvant therapy following resection in eligible adults. Crizotinib has a US indication for adults with metastatic ALK-positive or ROS1-positive disease identified by an approved test. An indication establishes eligibility. Selecting a regimen also requires the current disease-specific oncology protocol.2,3

Matching biomarkers to pharmacology

Molecular context Illustrative medicine/class Key clinical qualification
EGFR exon 19 deletion or L858R in NSCLC Osimertinib, an irreversible EGFR kinase inhibitor. FDA indications depend on stage and treatment setting; monitor ILD/pneumonitis, cardiomyopathy, QT effects and adverse reactions.2
ALK or ROS1 rearrangement in selected NSCLC ALK/ROS1-directed TKIs, including crizotinib in eligible settings. Multiple newer agents may be preferred in certain situations; test the exact fusion and consider CNS activity and prior therapy.3
HER2 overexpression/amplification Trastuzumab, HER2 kinase-directed or antibody–drug conjugate treatments. HER2-positive, HER2-low and HER2-ultralow are not interchangeable categories across cancers or products.4,5
BRCA/HRR abnormalities in selected tumors Olaparib and other PARP inhibitors. Eligibility depends on specific cancer type, stage, prior treatment and precise molecular criterion; BRCA positivity alone does not authorize all uses.6
Other actionable drivers BRAF, RET, NTRK, MET or other pathway inhibitors in selected indications. A mutation is not necessarily sensitive to every inhibitor targeting the same protein; variant class and evidence matter.1

NSCLC means non-small cell lung cancer. A finding in an archival biopsy may not reflect every tumor clone after several therapies, and a variant of uncertain significance is not automatically actionable. Molecular tumor boards can help when evidence, co-mutations or access are complicated.

How the main treatments work

Kinase inhibitors. Small molecules can reach intracellular targets and interrupt signalling that sustains tumour growth. The molecular alteration helps predict sensitivity. Cancer cells can subsequently acquire changes in the target or use another pathway, allowing progression despite an initial response.1

HER2-directed antibodies. Trastuzumab binds HER2 on the cell surface. The relevant tumour type and HER2 test determine eligibility. Cardiac function should be assessed before and during treatment because left ventricular dysfunction may develop, with greater risk during concurrent anthracycline exposure.4

Antibody–drug conjugates. Fam-trastuzumab deruxtecan-nxki couples a HER2-directed antibody to a topoisomerase I inhibitor payload. The conjugate has its own indications and toxicity profile. New cough, breathlessness or fever requires prompt investigation for interstitial lung disease. The label calls for permanent discontinuation for grade 2 or higher interstitial lung disease or pneumonitis.5

PARP inhibitors. Olaparib interferes with DNA repair. Eligibility depends on the cancer, previous therapy and the biomarker specified for the indication. A BRCA finding alone is insufficient to select treatment across all cancers. Blood counts require monitoring because cytopenias can occur. Persistent abnormalities warrant evaluation, including for myelodysplastic syndrome or acute myeloid leukaemia.6

Mechanisms of resistance

Targeted drugs can induce a dramatic initial response, but resistant tumor populations may emerge. Mechanisms include secondary mutations in the drug target, activation of bypass signaling pathways, gene amplification, histologic transformation or selection of preexisting resistant clones. Resistance is not always proof that the original treatment was unnecessary; it may reflect evolution under selective pressure.1

At progression, clinicians assess the pattern of relapse, performance status, prior toxicity and the need for tissue or plasma re-testing. A new biopsy can sometimes identify a resistance alteration that changes the next treatment; alternatively, local treatment of limited progressive lesions may be considered in highly selected patients. Never switch between targeted drugs solely because they inhibit the same broad pathway.

Administration and pharmacokinetics

Small-molecule tyrosine kinase inhibitors (TKIs) are often oral and can have clinically important CYP3A, transporter, acid-suppression and food interactions, but these vary greatly between agents. Monoclonal antibodies are usually parenteral and have different distribution and clearance mechanisms, sometimes involving target-mediated disposition. Antibody–drug conjugates (ADCs) combine an antibody, linker and cytotoxic payload, so clinical effects depend on target recognition, internalization, linker cleavage and payload release.

For example, fam-trastuzumab deruxtecan-nxki (ENHERTU) is an HER2-directed ADC with a topoisomerase I inhibitor payload. Its boxed warning includes interstitial lung disease/pneumonitis and embryo-fetal toxicity. New cough, fever or breathlessness requires immediate assessment; the label directs permanent discontinuation for grade 2 or higher ILD/pneumonitis. These risks cannot be inferred from standard trastuzumab alone.5

Monitoring during treatment

The mechanism guides the questions to ask at follow-up. For a patient receiving trastuzumab, a change in exercise tolerance should prompt assessment for cardiac dysfunction. For someone taking an oral kinase inhibitor, review the medicines taken alongside it and follow that product’s laboratory and interaction guidance. A dose adjustment appropriate for one inhibitor cannot be transferred to another solely because both inhibit kinases.4,3,2

Immune checkpoint inhibitors are a distinct form of cancer immunotherapy. They can cause inflammation involving the lungs, bowel, liver or endocrine organs. New symptoms during or after treatment require assessment for immune-mediated toxicity. Product-specific warnings and the site of injury determine management.7

Mechanism-based adverse effects and monitoring

Medicine/class Potential severe risk Monitoring priority
HER2-directed trastuzumab Left ventricular dysfunction and infusion reactions. Clinical cardiac assessment and echocardiography/other ejection-fraction testing per protocol.4
EGFR-directed TKIs Rash/diarrhea; selected agents cause ILD, QT prolongation or cardiomyopathy. Clinical respiratory, cardiac and drug-interaction review.2
ADCs such as trastuzumab deruxtecan ILD/pneumonitis, cytopenias, GI toxicity and fetal harm. New respiratory symptoms, blood counts and product-specific dose holds.5
PARP inhibitors Anemia and other cytopenias, rare MDS/AML. Complete blood counts and evaluation of persistent marrow abnormalities.6
Checkpoint inhibitors Immune-mediated colitis, pneumonitis, hepatitis and endocrinopathies. Symptom-directed assessment and disease-specific toxicity pathways; these agents are immunotherapy, not conventional driver-directed TKIs.7

New severe dyspnea, chest pain, bleeding, persistent fever, sudden neurological changes or rapidly progressive diarrhea during treatment demands urgent evaluation. Medication holds, dose reductions and steroid management for immune toxicities must follow the specific oncology protocol, not a generic internet table.

Does targeted therapy replace chemotherapy?

Not necessarily. Targeted drugs may be used alone, with cytotoxic chemotherapy, with hormonal therapy or in carefully selected sequences. Curative, adjuvant, neoadjuvant and metastatic contexts have different evidence. An eligible mutation does not guarantee that targeted therapy is preferred in every line of treatment, and the standard can change as trials establish newer approaches.

For complementary mechanisms and essential drug-safety issues, see cytotoxic chemotherapy pharmacology and safety.

Frequently asked questions

Does an actionable mutation always mean the drug will work?

No. Benefit depends on the exact variant, tumor context, resistance mechanisms and treatment history.

Are antibody–drug conjugates free of chemotherapy-related toxicity?

No. They deliver a cytotoxic payload and can cause substantial organ injury, marrow effects or ILD.5

Can I take a kinase inhibitor with any herbal supplement?

No. Some TKIs have important metabolic and transporter interactions; all products should be reviewed by the oncology pharmacist.

Does HER2-positive mean the same thing in every cancer?

No. Assay type, staining threshold and approved indication differ by tumor and drug.

Is a checkpoint inhibitor a traditional targeted small molecule?

No. It alters immune regulatory signaling and requires distinct immune-toxicity management.

References

  1. National Cancer Institute. Targeted therapy to treat cancer [Internet]. [cited 2026 Nov 10]. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies?redirect=true
  2. AstraZeneca. TAGRISSO (osimertinib) prescribing information [Internet]. [cited 2026 Nov 10]. Available from: https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=professional&setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7
  3. Pfizer. XALKORI (crizotinib) prescribing information [Internet]. [cited 2026 Nov 10]. Available from: https://labeling.pfizer.com/showlabeling.aspx?id=676
  4. Genentech. HERCEPTIN (trastuzumab) prescribing information [Internet]. [cited 2026 Nov 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?name=HERCEPTIN&setid=492dbdb2-077e-4064-bff3-372d6af0a7a2
  5. US Food and Drug Administration. ENHERTU (fam-trastuzumab deruxtecan-nxki) prescribing information [Internet]. [cited 2026 Nov 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761139s041s043lbl.pdf
  6. AstraZeneca. LYNPARZA (olaparib) prescribing information [Internet]. [cited 2026 Nov 10]. Available from: https://medicalinformation.astrazeneca-us.com/prescribing-information/lynparza.html
  7. National Cancer Institute. Organ-related inflammation and immunotherapy [Internet]. [cited 2026 Nov 10]. Available from: https://www.cancer.gov/about-cancer/treatment/side-effects/organ-inflammation

⚠️ Medical Disclaimer

This article is intended for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.

The information provided here is based on current scientific literature and established pharmacological principles. However, medical knowledge evolves continuously, and individual patient responses to medications may vary. Healthcare professionals should always use their clinical judgment when applying this information to patient care.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *